Bio-Rad Laboratories Inc. (BIO)
NYSE: BIO
· Real-Time Price · USD
229.09
-1.27 (-0.55%)
At close: May 28, 2025, 3:59 PM
232.16
1.34%
After-hours: May 28, 2025, 07:46 PM EDT
-0.55% (1D)
Bid | 217 |
Market Cap | 6.25B |
Revenue (ttm) | 2.54B |
Net Income (ttm) | -2.23B |
EPS (ttm) | -76.53 |
PE Ratio (ttm) | -2.99 |
Forward PE | 22.6 |
Analyst | Buy |
Ask | 245.6 |
Volume | 216,184 |
Avg. Volume (20D) | 373,955 |
Open | 229.75 |
Previous Close | 230.36 |
Day's Range | 227.76 - 230.62 |
52-Week Range | 215.38 - 387.99 |
Beta | 1.00 |
Analyst Forecast
According to 0 analyst ratings, the average rating for BIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-1.5%
Bio-Rad Laboratories shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
-1.92%
Bio-Rad Laboratories shares are trading lower after the company missed Q4 revenue estimates.

3 weeks ago · seekingalpha.com
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call TranscriptBio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Opera...

2 months ago · prismmediawire.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsIRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth q...